9 stories mentioning HKG:3320Updated 12d ago
Every FINWIRES story that references HKG:3320, newest first.
China Resources Pharmaceutical's (HKG:3320) unit China Resources Pharmaceutical Holdings completed the issue of 1 billion yuan of three-year bonds carrying a 1.53% coupon rate.The unit will use proceeds to replenish working capital and repay debt among other purposes, according to a Wednesday Hong Kong bourse filing.
China Resources Pharmaceutical's (HKG:3320) indirect subsidiary China Resources Double-Crane Pharmaceutical (SHA:600062) has emerged as the top bidder to acquire a 23.5% stake in Lier Chemical (SHE:002258), according to a Wednesday Hong Kong bourse filing.Double-Crane ranked first in a public bidding process for 188.1 million shares being sold by Sichuan Jiuyuan Investment and Sichuan Huacai Technology. It currently holds no interest in Lier Chemical, the filing said.The company said the potential acquisition would support its synthetic biology strategy by strengthening its presence in crop and animal protection, one of its four core focus areas.The transaction remains subject to the execution of definitive agreements and satisfaction of customary conditions, and may or may not proceed.
China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) recorded a 7.9% decline in attributable profit for the first half of 2026 to 1.67 billion yuan from 1.82 billion yuan a year prior.Basic EPS fell to 1 yuan from 1.09 yuan in the corresponding period of the previous fiscal year, according to a Tuesday filing by parent China Resources Pharmaceutical (HKG:3320).The pharmaceutical company's operating revenue increased 1.4% to 15 billion yuan from 14.8 billion yuan previously.
China Resources Pharmaceutical (HKG:3320) unit China Resources Pharmaceutical Commercial Group completed the issue of 2 billion yuan of 1.59% corporate bonds in China maturing in three years, according to a Friday Hong Kong bourse filing.The pharma firm intends to use proceeds for production expenditures, including the replenishment of working capital, repayment of debt, and project investments.
A unit of China Resources Pharmaceutical Group (HKG:3320) obtained a registration acceptance notice for the proposed issue of medium-term bonds from the National Association of Financial Market Institutional Investors, according to a May 29 Hong Kong bourse filing.Shares of the pharmaceutical firm were up over 2% in Monday afternoon trading.The acceptance will allow unit China Resources Pharmaceutical Holdings to issue up to 5 billion yuan of bonds in various tranches within two years.Proceeds from the issue are expected to be used to replenish working capital and repay debt among other uses.
China Resources Pharmaceutical (HKG:3320) unit China Resources Pharmaceutical Commercial Group completed the issue of 1.4 billion yuan of 1.65% corporate bonds in China maturing in three years, according to a Tuesday Hong Kong bourse filing.The pharma firm intends to use proceeds for production expenditures, including the replenishment of working capital, repayment of debt, and project investments.
Dong-E-E-Jiao (SHE:000423) posted net profit of 454.8 million yuan for the first quarter of 2026, up 7% from 424.6 million yuan a year earlier, according to a Shenzhen bourse filing over the weekend.Earnings per share edged up to 0.7080 yuan from 0.6615 yuan.Revenue rose 5.5% to 1.81 billion yuan from 1.72 billion yuan in the prior-year period.The donkey-hide gelatin producer is a unit of China Resources Pharmaceutical (HKG:3320).
China Resources Double-Crane Pharmaceutical (SHA:600062) posted net profit of 501.4 million yuan for the first quarter of 2026, down from 522.7 million yuan a year earlier, according to an April 24 Hong Kong bourse filing by parent China Resources Pharmaceutical (HKG:3320).Revenue fell to 2.81 billion yuan from 3.08 billion yuan in the prior year period.
China Resources Pharmaceutical (HKG:3320) unit China Resources Pharmaceutical Holdings completed the issue of 1.5 billion yuan of corporate bonds to qualified investors in China, according to a Thursday Hong Kong bourse filing.The bonds carry a coupon rate of 1.65% per annum and will fall due in three years.The unit will use proceeds for corporate debt repayment, working capital replenishment, project development and operation expenditures, certain investments, and other purposes.
